Cervical intraepithelial neoplasia in women who had vaccination against HPV. Issue 2 (8th August 2019)

• Record Type: Journal Article
• Authors: Bogani, Giorgio; Serati, Maurizio; Leone Roberti Maggiore, Umberto; Ditto, Antonino; Gardella, Barbara; Ferrero, Simone; Spinillo, Arsenio; Ghezzi, Fabio; Raspagliesi, Francesco
• Is Part Of: International journal of gynaecology and obstetrics. Volume 147:Issue 2(2019)
• Page Start: 233
• Page End: 237
• Publication Date: 2019-08-08
• Subjects: Cervical dysplasia -- HPV -- Human papillomavirus -- Nonavalent vaccination -- Vaccination; Gynecology -- Periodicals; Obstetrics -- Periodicals; Electronic journals; 618
• DOI: 10.1002/ijgo.12934
• Languages: English
• ISSNs: 0020-7292

Abstract

Abstract: Objective: To investigate the characteristics of women developing cervical intraepithelial neoplasia who had had a vaccination against human papillomavirus (HPV). Methods: A retrospective cohort study was carried out of women diagnosed with moderate or severe cervical dysplasia (CIN2+) in four Italian centers between 2015 and 2017. All women included had had previous bivalent or quadrivalent vaccination against HPV. Results: The present study included 43 patients affected by CIN2+. The median age was 28 (range, 21–41) years. Ten (23.3%) patients did not have a diagnosis of specific HPV type(s) involved: high‐risk HPV was detected in 7 (16.3%) women while HPV testing was negative in 3 (6.9%) women. Lesions related to HPV16 were found in two patients. HPV types covered by nonavalent vaccination were diagnosed in 27/33 (81.8%) women. HPV types not covered by nonavalent vaccination were diagnosed in 6 (18.2%) women. Co‐infections are most commonly detected in women with HPVs other than those included in the nonavalent vaccination ( P =0.024). Conclusion: Cervical dysplasia occurring after HPV vaccination is a rare condition. Theoretically, nonavalent vaccination should improve protection against more than 80% of HPV‐related lesions compared to other vaccines. Abstract : More than 8 out of 10 patients developing cervical dysplasia after having a vaccination would have been protected if they had used the nonavalent vaccine.